-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Various anti-programmed cell death (ligand)-1 (PD-[L]1) immune checkpoint inhibitors are approved for the treatment of advanced/metastatic urothelial carcinoma (mUC)
.
Recently, an anti-PD-1/anti-cytotoxic T-cell lymphocyte-4 (CTLA-4) combination regimen was reported to have improved therapeutic activity compared with anti-PD-1 monotherapy
Recently, a study was published in the Journal of Clinical Oncology, a top international journal, reporting a response-based regimen of nivolumab monotherapy followed by nivolumab/ipilimumab.
Strengthen immunotherapy
.
Research Process
Research ProcessIn this study, patients received nivolumab induction therapy (4 doses), and those who responded continued to receive nivolumab maintenance therapy
.
If unresponsive to initial intensive therapy, patients with stable or progressive disease receive nivolumab (3 mg/kg 3 weeks x 2 doses) in combination with ipilimumab (1 mg/kg 3 weeks x 2 doses) followed by nivolumab Monoclonal antibody (1 mg/kg 3 weeks x 2 doses) combined with ipilimumab (3 mg/kg 3 weeks x 2 doses)
Progression-Free Survival and Overall Survival
Progression-Free Survival and Overall SurvivalBetween July 2017 and April 2019, a total of 86 patients (median age, 68 years) were enrolled, of which 42 were first-line therapy (1L), 39 were second-line therapy (2L), and 5 were Third-line therapy (3L)
.
The median follow-up was 7.
The objective response rate for patients treated with nivolumab monotherapy as first or second/third line was 29% and 23%, respectively, for patients treated with nivolumab monotherapy as first or second/third line therapy was 29 % and 23% of patients with and without intensive nivolumab/ipilimumab had objective response rates of 45% and 27%, respectively
The study's tailored nivolumab therapy demonstrated significant clinical activity, supporting dual-checkpoint inhibitor therapy in first-line treatment of patients with metastatic urothelial carcinoma .
Original source:
Original source:Marc-Oliver Grimm, et al.
leave a message here
